Completed PHASE2 INTERVENTIONAL NCT00044070

A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion, and FLAIR Magnetic Resonance Imaging in Patients With Acute Ischemic Stroke

Sponsor: Astellas Pharma Inc

Conditions Cerebrovascular Accident

Interventions YM872 (zonampanel)

Updated 6 times since 2017 Last updated: Mar 31, 2006 Started: Dec 31, 2000 Completion: Jan 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cerebrovascular Accident and is currently completed. Astellas Pharma Inc leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Astellas Pharma US, Inc.

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Albany, United States , Albuquerque, United States , Arcadia, South Africa , Baltimore, United States , Bloemfontein, South Africa , Boston, United States , Boynton Beach, United States , Bridgeport, United States , Brussels, Belgium and 74 more locations